Abstract: Objective To compare the therapeutic effects of Palitaxel and Ifosfamide for malignant gynecological tumors. MethodsIn the Palitaxel group, 27 cases had ovarian cancer, 6 had fallopian tube cancer, 3 had cervical cancer, and 1 had endometrium cancer; 33 cases had been subjected to surgeries or relapsed after chemotherapies, and 4 were primary ovarian cancer. In the ifosfamide group, 30 cases had ovarian cancer, 3 had fallopian tube cancer, 3 had cervical cancer, and 1 had endometrium cancer; all had relapsed after chemotherapies. In the Palitaxel group, Palitaxel(135-150mg/m²) was intravenously or intraperitonially administered once every three weeks in combination with carboplatin(60mg). In the Ifosfamide group, Ifosfamide(2.0g)was administered in combination with carboplatin(60mg). Antihistaminics and anti-emetic were given prior to Palitaxel. ResultsThe overall median survival time was 25 months in the Ifosfamide group and was 37 months in the Palitaxel group (P＜0.001). The response rate was 28% and 48.6%, respectively (P＜0.001). The major toxic effects were myelosuppression and alopecia. ConclusionPalitaxel is effective in the treatment of advanced gynecological tumors.

Key words: Ovarian neoplasms, Fallopian tube neoplasms, Palitaxel, Ifosfamide, Carboplatin